The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

QIAstat-Dx uses real-time PCR technology to multiply genetic targets within the same reaction and deliver test results in ...

Anaconda Biomed S.L. announced that it named Trent Reutiman its new CEO. The company’s previous CEO Francois Salmon will n ...

Throughout last year, Qiagen was granted FDA clearance for four QIAstat-Dx ... QIAstat-Dx system operations in Esplugues de Llobregat, Barcelona, Spain. Due to open early next year, the new ...